DOI QR코드

DOI QR Code

Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India

  • Doval, Dinesh Chandra (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Sharma, Anila (Department of Laboratory Services, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Sinha, Rupal (Department of Research, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Kumar, Kapil (Department of Surgical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Dewan, Ajay Kumar (Department of Surgical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Chaturvedi, Harit (Department of Surgical Oncology, MAX Hospital) ;
  • Batra, Ullas (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Talwar, Vineet (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Gupta, Sunil Kumar (Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre) ;
  • Singh, Shailendra (Auriga Life Sciences) ;
  • Bhole, Vidula (Episolutions Consultancy Services) ;
  • Mehta, Anurag (Department of Laboratory Services, Rajiv Gandhi Cancer Institute & Research Centre)
  • Published : 2015.07.13

Abstract

Background: To assess the immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) neu receptor in breast cancer and their associations with various clinicopathological characteristics. Materials and Methods: This is a retrospective analysis of women who presented with primary, unilateral breast cancer in the Department of Medical Oncology at Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India during the period from January 2008 to December 2011. Data were retrieved from the medical records of the hospital including both early and locally advanced cancer cases. ER, PgR and HER2neu expression in these patients was assessed and triple negative patients were identified. Associations of triple negative and non-triple negative groups with clinicopathological characteristics were also evaluated. Results: A total of 1,284 women (mean age 52.1 years, 41.9% premenopausal) were included in the analysis. Hormone receptor positivity (ER and/or PgR) was seen in 63.4% patients, while 23.8% of tumors were triple negative. Only 23.0% were HER2 positive. Around 10.0% of tumors were both ER and HER2 positive. ER and PgR positivity was significantly associated with negative HER2 status (p-value <0.0001). Younger age, premenopausal status, higher tumor grade, lymph node negativity, advanced cancer stage, and type of tumor were strongly associated with triple negativity. Significantly, a smaller proportion of women had ductal carcinoma in situ in the triple negative group compared with the non-triple negative group (35.6% versus 60.8%, p-value<0.01). Conclusions: The present analysis is one of the largest studies from India. The majority of the Indian breast cancer patients seen in our hospital present with ER and PgR positive tumors. The triple negative patients tended to be younger, premenopausal, and were associated with higher tumor grades, negative lymph nodes status and lower frequency of ductal carcinoma in situ.

Keywords

Breast cancer;immunohistochemistry;hormone receptors;India

References

  1. Patil AV, Bhamre RS, Singhai R, et al (2011a). Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women. Breast Cancer (Dove Med Press), 3, 27-33.
  2. Patil VW, Singhai R, Patil AV, et al (2011b). Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer (Dove Med Press), 3, 9-19.
  3. Perez EA, Romond EH, Suman VJ, et al (2011). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 29, 3366-73. https://doi.org/10.1200/JCO.2011.35.0868
  4. Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
  5. Shet T, Agrawal A, Nadkarni M, et al (2009). Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol, 52, 171-4. https://doi.org/10.4103/0377-4929.48909
  6. Singhai R, Patil V, Patil A (2011). Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women. Asian Pac J Cancer Prev, 12, 179-83.
  7. Vaidyanathan K, Kumar P, Reddy CO, et al (2010). ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer, 47, 8-15. https://doi.org/10.4103/0019-509X.58852
  8. Zhang SJ, Hu Y, Qian HL, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40. https://doi.org/10.7314/APJCP.2013.14.6.3937
  9. Ambroise M, Ghosh M, Mallikarjuna VS, et al (2011). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev, 12, 625-9.
  10. Babu GR, Lakshmi SB, Thiyagarajan JA (2013). Epidemiological correlates of breast cancer in South India. Asian Pac J Cancer Prev, 14, 5077-83. https://doi.org/10.7314/APJCP.2013.14.9.5077
  11. Badve S, Dabbs DJ, Schnitt SJ, et al (2011). Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol, 24, 157-67. https://doi.org/10.1038/modpathol.2010.200
  12. Basu S, Chen W, Tchou J, et al (2008). Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer, 112, 995-1000. https://doi.org/10.1002/cncr.23226
  13. D'Souza ND, Murthy NS, Aras RY (2013). Projection of cancer incident cases for India -till 2026. Asian Pac J Cancer Prev, 14, 4379-86. https://doi.org/10.7314/APJCP.2013.14.7.4379
  14. Dogra A, Doval DC, Sardana M, et al (2014). Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. Asian Pac J Cancer Prev, 15, 10577-83.
  15. Dowsett M, Houghton J, Iden C, et al (2006). Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol, 17, 818-26. https://doi.org/10.1093/annonc/mdl016
  16. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  17. Group EBCTC (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
  18. J Ferlay ISI, M Ervik, R Dikshit, et al (2012). Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [Online]. [Accessed 15 April 2015].
  19. Manjunath S, Prabhu JS, Kaluve R, et al (2011). Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype? Indian J Surg Oncol, 2, 122-5. https://doi.org/10.1007/s13193-011-0072-8
  20. Munjal K, Ambaye A, Evans MF, et al (2009). Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev, 10, 773-8.

Cited by

  1. Shikonin Induced Necroptosis via Reactive Oxygen Species in the T-47D Breast Cancer Cell Line vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7261
  2. Association of Histopathological Markers with Clinico-Pathological Factors in Mexican Women with Breast Cancer vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8397
  3. Relationship between HER2 Proto-oncogene Status and Prognostic Factors of Breast Cancer in the West of Iran vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.295
  4. Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients vol.25, pp.4, 2018, https://doi.org/10.1007/s12282-018-0840-1